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A B S T R A C T
In this paper, we investigate the ways in which a group of scientists in Edinburgh worked across mice and sheep
during the last quarter of the twentieth century. With this local episode, we show the utility of an interspecies
perspective to investigate recent historical transformations in the life sciences. We argue that the emergence of
animal biotechnology was the result of interactions between neoliberal policymakers, science administrators,
molecular biologists, agricultural breeders, and the laboratory and farm organisms with which they worked.
During the early 1980s, all these actors believed that the exportation of genetic engineering techniques from
mice to farm animals would lead to more effective breeding programmes in the agricultural sciences. However,
the circulation of people, money, expertise and infrastructures that the experiments required, as well as the
practical constraints of working with mice and sheep, resisted a simple scaling-up from one organism to the
other. This displaced the goals of the Edinburgh scientists from the production of transgenic sheep to stem cell
research and human regenerative medicine. We account for this unexpected shift by looking at the interplay
between science policy and its implementation via collective action and bench work across different organisms.
The emergence of animal biotechnology in Edinburgh also provides historiographical insights on the birth of
Dolly the sheep and, more generally, on the interactions between the molecular and the reproductive sciences at
the fall of the twentieth century.
1. Introduction
In June 1985, the European Commission sponsored a seminar on
New Technologies in Animal Breeding in Edinburgh. The local organisers
were the Animal Breeding Research Organisation (ABRO) and the
Poultry Research Centre (PRC), two publicly-funded reference institu-
tions with almost 40 years of experience in the field of animal genetics –
eight years later, in 1993, they would both merge into the Roslin
Institute, celebrated for the cloning of Dolly the sheep (Franklin, 2007;
García-Sancho, 2015). The papers that were presented at the seminar
captured how ongoing socio-political transformations, together with
the spread of new techniques, were placing farm animal and, more
generally, agricultural research at a crossroads. While some presenta-
tions addressed more traditional approaches, such as physiological,
biochemical and genetic optimisation of breeding processes, others
embraced recombinant techniques that allowed the direct alteration of
the animals’ DNA. These techniques had been invented in the 1970s and
adapted to mammals, notably mice. Their promise for agriculture was
enormous and the European Communities – precursor of the European
Union – were eager to catch up on a development that had mainly taken
place in the United States (US).
In one of the ABRO presentations, a team led by molecular biologist
Richard Lathe described what came to be known as the pharming
project. This project used recombinant DNA techniques to modify
sheep, so that they would produce therapeutic proteins for human
consumption in their milk. The pharming project had a commercial
angle, but unlike the breeding research that had taken place in ABRO so
far, it was targeted to pharmaceutical companies rather than the
farming sector (hence ‘pharming’ as a portmanteau of farming and
pharmaceuticals). Lathe's group inspiration was the genetic modifica-
tion of mice, first reported in 1980.
By the time of the seminar, several groups in the US and Europe had
introduced and expressed genes from other species – viruses, rabbits,
rats, and humans – in mice. These genetically modified animals were
called “transgenic” (Gordon & Ruddle, 1981, p. 1244) and achieved
increasing popularity throughout the 1980s. Most dramatically, in 1982
Ralph Brinster, Richard Palmiter and colleagues in the US published
results of mice modified with rat growth hormone genes that grew to
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almost twice the normal size. With their image on the cover of Nature
and circulating widely in magazines and newspapers, these supermice
were the first visible testament to the power of transgenic technology.
Lathe and his colleagues in Edinburgh presented their research as an
“extension to farm animals” of the results successfully achieved in mice
(Lathe et al., 1986, p. 91).
Mice had been used in genetics since the dawn of the field around
1900, becoming a major laboratory organism with associated knowl-
edge, practices, and infrastructures (Rader, 2004). In the 1950s and
1960s, mouse use expanded dramatically with cancer research, and the
rodents were used in huge numbers in large-scale screens of radiation,
carcinogens and tumour viruses (Löwy & Gaudillière, 1998, pp.
209–249). Since their early domestication by geneticists at Harvard,
Cold Spring Harbor, and later the Jackson Laboratory, their mammalian
status made them a model for human health. In Jessica Bolker's (2009)
terms, these were surrogate models for human health, but also ex-
emplary models, in that they represented mammals as a whole. This
status made mice ideal for research into farm animal health and
breeding. Both ABRO and the PRC had incorporated lines of work on
mice since very early after their creation, in the mid-twentieth century.
Historians and philosophers of biology have paid much attention to
model organisms, a phrase that gained currency in the life sciences
during the 1980s. Yet the specific practices of modelling from one or-
ganism or species to another have proved diverse and elusive. These
practices of “working across species” are attracting increasing scholarly
interest. They encompass actions beyond a simplistic notion of model-
ling, among them comparison of results (Mason Dentinger & Woods,
2018), investigation of biological processes underlying different or-
ganisms (Ankeny & Leonelli, 2011), and adaptation of medical knowl-
edge – often, but not always, from other animals to humans (Kirk &
Worboys, 2011). A common conclusion of this scholarship is that in-
terspecies work is not a simple scalar process, and the translation of
results across organisms defies naïve analogies, straightforward plan-
ning, or linear progression (Nelson, 2013; Slater, 2005). Adele Clarke
and Carrie Friese (2012) have stressed that interspecies work can
achieve productive results, as routine extrapolations allow for new re-
search agendas. Scientists overcome the challenges of “transposition”
from one model to another by creating dynamic relations between ex-
perimental organisms that can change along with the social world in
which the research is conducted.
In this article, we investigate an unusual role for mice as models in
agricultural genetics at a time of great upheaval in Britain.1 Re-
combinant DNA stirred dramatic debates, but also attracted great hopes
for biological intervention and precision of genetic manipulation. In the
early 1980s, it also proved a political lifeline for animal breeding, as the
fledging biotechnology industry promised avenues to commercialising
research, in the general context of cuts to agricultural sciences under
Margaret Thatcher and neoliberal governments elsewhere (Myelnikov,
2017). Scientists at ABRO and their funder, the Agricultural Research
Council (ARC), eagerly observed transgenic mice, with the pharming
project being an attempt to export the technique to sheep and, even-
tually, other farm animals. The pharming project adopted mice as
prototypes for expressing useful proteins in sheep milk.
Sheep rather than humans were thus the targets of modelling, while
human patients were placed as future consumers of the resulting ther-
apeutic proteins. We will show how the growing focus on recombinant
DNA work that privileged genes and their expression as a unifying
principle for biological research enabled new kinds of experiments in
the field of animal breeding. These new experiments received great
institutional priority and reoriented local research programmes in
Edinburgh, as infrastructures that placed mice and sheep together were
being improvised. In 1990, the pharming project succeeded with the
birth of Tracy, one of the first transgenic sheep and the first to express
large amounts of a human therapeutic protein. Yet the road to Tracy
was not a clear scaling-up from mice to sheep; rather, genes, techni-
ques, and scientists circulated back and forth across the two organisms,
often leading to unexpected outcomes.
In what follows, we will address the convolutedness of this mouse-
to-sheep work and present it as a novel lens to look at the history of
animal biotechnology. We will argue that a main reason for this in-
terspecies complexity was the multiplicity of actors, places, institutions
and experimental organisms involved in bringing the pharming project
to fruition, both at the level of scientific policy and laboratory work.
The different interests and expertise operating, as well as the need to
redefine infrastructures that were already in place around mice and
sheep in Edinburgh, created shifts in the work across species.
Sometimes, the results on sheep came quicker than those on mouse, this
disrupting – and even inverting – the interspecies narrative that Lathe
and his colleagues had formulated. This back-and-forth process chal-
lenged the expectation of recombinant DNA being a unifying tool for
biology: instead, the circulation of this technique from mouse to sheep
resembled a “dance of agency” (Pickering, 1995, p. 21ff.) between the
many agendas and constraints at stake.
2. Biotechnology as interspecies work
By the time of the 1985 European seminar, ABRO and the PRC
were facing an enormous financial and scientific uncertainty. These
institutions had been founded between 1945 and 1947, in the face of
the food rationing and animal disease problems derived from World
War II. Over the following decades, they had consolidated as the
flagship animal breeding organisations of Britain, and developed an
extensive portfolio of programmes aimed at improving the commer-
cial yield and health of cattle, pig and chicken, among other species.
This leadership position had been achieved thanks to continuous
funding from the Agricultural Research Council (ARC, the body of the
British Government managing plant and animal research), and
fruitful interactions with scientists at the University of Edinburgh
(Cooke, 1981, especially pp. 277–288).
The early interactions between the Edinburgh breeding institutions
and the University had been channelled through the Institute of Animal
Genetics (IAG). The IAG had grown out of the Animal Breeding
Research Department at the University and by the 1930s had con-
solidated as a leading institution in quantitative genetics – a subfield
that addressed gradable characteristics of organisms, as opposed to
qualitative Mendelian genetics (Button, 2017). In 1947, as ABRO and
the PRC were being founded, the IAG made two key appointments in C.
H. Waddington and Douglas Falconer. The former established an in-
fluential line of research that investigated the genetics of embryonic
and post-embryonic development in the fruit fly, Drosophila melanoga-
ster. The latter devised a methodology that enabled geneticists to pre-
dict features such as litter size in successive generations of mice. Ac-
cording to Falconer, there was a gradation between the organisms on
which the Edinburgh geneticists worked, so that “any breeding method
that might be based on the Drosophila results” would be tested “cheap
and quick” in mice “and if it worked it could be applied with more
confidence to farm animals” (Falconer, 1993, p. 139).
This led to growing collaboration between ABRO, the PRC and the
IAG. The Edinburgh farm animal geneticists increasingly adopted
Falconer's methodology and used mice as prototypes to design livestock
breeding programmes. Mice had a shorter life cycle, “no economic
value to jeopardise” and shared “a considerable inheritance with cattle,
1 Our main source is the recently available archive of the Roslin Institute and
its predecessor institutions at the University of Edinburgh: https://collections.
ed.ac.uk/towardsdolly/catalogues (last accessed January 2019). Historians and
social scientists have amply investigated the use of mice, but often restricting
their analysis to scientific fields in which the rodents modelled human pro-
cesses. By looking at work across mice and other non-human organisms, we
align with appeals to overcome the anthropocentrism of current literature (Kirk
& Worboys, 2011; Mason Dentinger & Woods, 2018).
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sheep and pigs.”2 During the post-war and Cold War years, extrapola-
tion of mouse results led to ambitious initiatives, such as the Hereford
project that explored the long-term costs and benefits of cow inter-
breeding at different British farms. Mice were also used as models for
scrapie, a common sheep condition, in a programme developed with the
Animal Diseases Research Association, a group of Scottish farmers that
funded agricultural science.3
The proliferation of breeding research in Edinburgh – and more
generally in Britain – finished rather abruptly during the 1970s. By that
time, the problem of feeding the population after the War had largely
been solved, and agricultural science was regarded as increasingly old-
fashioned and unnecessary. In 1971, Lord Rothschild issued a report in
which he urged publicly-funded research institutions to address tan-
gible, national necessities instead of abstract academic interests. A
former head of the ARC, Rothschild considered that science adminis-
tration had been conducted inefficiently and moved 60% of ABRO's
budget to the Ministry of Agriculture, Fisheries and Food (MAFF),
where funding needed to be justified by practical outcomes (Parker,
2016; Thirtle, Palladino, & Piesse, 1997). The view that was becoming
dominant in the UK was that the production of new plant and animal
varieties should be left to the private sector, with state-funded institu-
tions rather focusing on innovative breeding methods, ideally in col-
laboration with industry. The European Economic Communities –
which Britain joined in 1973 – were by then facing food surplus issues
and one of the objectives of the Common Agricultural Policy was
shifting the focus from production to productivity and innovation
(Garcia-Sancho, Myelnikov, & Lowe, 2017, p. 14).
The most popular innovation in the life sciences at the time was
recombinant DNA, a set of techniques that was invented by a young
breed of molecular biologists, with key experiments at Stanford
University and the University of California, San Francisco. These tech-
nologies allowed the transfer of genetic material from one organism to
another: in 1974, their inventors successfully inserted a frog gene into
the bacterium E. coli. Soon, genetically modified bacteria were por-
trayed by scientists, policy-makers and commentators as potentially
unlimited resources for the controlled expression of genes that pro-
duced substances of practical interest (Bud, 2010). Biotechnology start-
up companies, like the Bay Area–based Genentech, sprung up to pro-
duce human insulin and somatostatin from bacteria. From the earliest
days, agricultural applications were seen as an important aspect of the
new techniques, and following the first experiments at Stanford the New
York Times headline noted “animal gene shifted to bacteria: aid seen to
medicine and farm” (Yi, 2015, quote from p.2).
Recombinant DNA emerged at a time in which molecular biology
was seeking to expand its knowledge frontier from microorganisms to
higher animals. Prior to the 1974 results, molecular biologists had built
their prestige and reputation through experimental systems formed by
viruses that expressed their genes in the bacterium E. coli. These sys-
tems were developed by Francois Jacob, Jacques Monod and other
Nobel-awarded founders of molecular biology. They proved remarkably
productive as “exemplars” of the biological mechanism of gene ex-
pression (Creager, 2002, ch. 8). In the mid-1970s, Jacob and colleagues
shifted to multi-cellular organisms – including mice – in an attempt to
address Monod's belief that “anything found to be true of E. coli must
also be true of elephants” (quote from Monod & Jacob, 1961, p. 393; see
also Morange, 2000).
This “mass migration” to higher organisms (Yi, 2015, ch. 2) was
fuelled by the expectation of recombinant DNA becoming a universal
tool unifying different fields of the life sciences. Molecular biologists
and other life scientists believed that recombinant DNA would foster a
new way of working across species, one based on the properties of
genes rather than modelling or comparing biological processes. This
would entail dealing with the supposedly universal language of DNA
rather than having to export knowledge from the biology of one species
into another: for instance, from mice to livestock in the design of
breeding programmes. During the late 1970s and 1980s, biological and
medical researchers enthusiastically adopted recombinant DNA, in
some cases without detailed knowledge of the workings of genes at the
molecular level.
Mouse geneticists and embryologists were among the most en-
thusiastic adopters, and Frank Ruddle at Yale University was the first to
announce his team's success in inserting a herpes virus gene into a mouse
genome. Ruddle's postdoc, Jon Gordon, had adapted the technique of
microinjection, which the lab had been using to modify cultured cells, to
introduce a DNA solution into one of the pronuclei (sperm or egg nu-
cleus) of a fertilised mouse egg. The Yale group published in December
1980, and in the following years more experiments flooded in – the bulk
of them had been initiated before Ruddle and Gordon's results. Between
1982 and 83, Ralph Brinster and Richard Palmiter of the Universities of
Pennsylvania and Washington, respectively, reported the most dramatic
result yet: giant mice or supermice were born after microinjection of their
embryos with rat growth hormone gene and later human growth hor-
mone gene (Myelnikov, 2015, ch. 4).
The extensive coverage of supermice triggered discussions about
their potential. The possibility of extending the genetic modification
technique to agriculture was, from the beginning, a major theme in
media reports, encouraged by Brinster and Palmiter's lively specula-
tions about the future. Speaking to Time magazine, Brinster said: “If we
can make bigger mice we can make bigger cows” – he had trained as a
vet and is based at the University of Pennsylvania's School of Veterinary
Medicine.4 Shortly after the supermice were announced, Brinster and
Palmiter started working with scientists at the US Department of
Agriculture (USDA) Agricultural Research Service in Beltsville, Mary-
land, and in 1985 announced genetically modified rabbits, sheep and
pigs. None of the foreign genes, however, seemed to make much dif-
ference to these animals (Hammer et al., 1985).
British science administrators observed the US developments with
keen interest. The early-to-mid 1980s were times of concern for state-
supported research institutions, following Margaret Thatcher's victory
in the 1979 general election. Thatcher had been Secretary of State for
Education and Science in Edward Heath's Conservative government
when the Rothschild Report was implemented (Agar, 2011). Thatcher's
governments shared the general rationale that had led to the commis-
sioning of the report: the efficiency of public administration and pro-
ductivity of state investment – including publicly-funded research –
needed to be maximised. In that regard, the extensive breeding pro-
grammes that had characterised the UK's agricultural science and re-
quired vast amounts of land, animals and multi-year funding, did not
align with the mantra of rapid delivery of results and impact on the
economy or healthcare system.
Recombinant DNA offered a lifeline and an opportunity for strug-
gling institutions at a time when the Thatcherite policies were feared,
but had not yet made a significant impact on budgets. In 1979, the same
year Thatcher was elected, the ARC appointed a new Secretary, Ralph
Riley, who had a longstanding interest in genetic modification of plants.
Riley soon explored this possibility as a more general solution for the
agricultural sciences and in April 1981, months after the first Yale
2 N. Bateman, “ABRO's mice,” ABRO Annual Report – January 1967, pp. 33–40
(quotations from p. 33-4). Edinburgh University Main Library, Special
Collections, Records of Roslin Institute and Predecessor Institutions, EUA IN23/
1/1/2.
3 C.G. Dickinson, “Catching (up with) scrapie,” and St. C.S. Taylor, “A
Multibreed approach to Breed Comparison,” ABRO Annual Report – January
1972, pp. 7–13 and 15–20. Edinburgh University Main Library, Special
Collections, Records of Roslin Institute and Predecessor Institutions, EUA IN23/
1/1/2. On ABRO's research on scrapie, see also Kim, 2007, ch3.
4 “Mighty Mice: Gene transfers create giants”, Time, 16 December 1982, p. 53.
See also J. Leith, “The Livestock Industry's Genetic Revolution,” Business Week,
21 June 1982, 124–32.
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paper, the ARC Animal Research Station in Cambridge held a meeting
on “Genetic Engineering in Domestic Animals.”5 One year afterwards,
in 1982, the ARC published a report reviewing the strategies of two of
its main research institutions, one of them being ABRO.
The ARC's belief was that rather than applying a blanket reduction
of resources across its centres, it was preferable to streamline its lines of
research to a few strategic areas. In its report, the ARC concluded that
ABRO's “large-scale breeding experiments” were “costly and inflexible,”
and that the Edinburgh institution “should not put direct effort into
developing new varieties of farm animals.” The future remit of ABRO
would rather become “relevant basic research” into the “genetics” of
livestock using “new advancements and techniques, such as molecular
biology.” It was “for these developments that additional funds would be
considered” (ARC, 1982: unnumbered pages).
The ARC's conclusions suggest that the adoption of genetic en-
gineering by British agricultural scientists was triggered by two his-
torical processes: 1) policy reforms that discouraged the public funding
of long-term breeding programmes, and 2) the expansion of re-
combinant DNA technologies from bacteria and viruses to mammals.
Yet neither of these processes made establishing genetic engineering as
a privileged line of research for agricultural science inevitable. It was
the collective action of scientists, politicians and administrators at
many levels – from the central government to the ARC and ABRO – that
led recombinant DNA to be seen as a promising horizon that would
transform the neoliberal policies into a productive rather than self-de-
structive scientific programme.6
This confluence of political and scientific agendas illustrates Barry
Barnes's notion of collective agency. In a seminal contribution to the
field of Science and Technology Studies (STS), Barnes argues that social
and scientific change cannot simply be attributed to the sum of in-
dividual, rational choices. The transformation of knowledge systems
and shared imaginaries requires the intertwined action of a variety of
actors who inhabit different social worlds and whose interests coalesce
in a contingent time and space (Barnes, 2000, p. 64ff). In the case of the
ARC and ABRO, what transformed many isolated interests into a col-
lective agency was the expectation that by scaling-up recombinant DNA
from bacteria to mice to farm animals, it would be possible to tailor
livestock breeding and make it more efficient in terms of the required
resources. This aligned the agendas of policymakers seeking to ratio-
nalise R&D funding and agricultural researchers wanting to both sur-
vive and thrive as scientists in the new austerity times. Out of this
alignment, the new field of animal biotechnology materialised. As the
genetic engineering of farm animals became an experimental reality,
the expectations and interspecies work underlying this new field were
substantially reconfigured.
3. The pharming project across people and space
Following the ARC announcement to downsize breeding research in
Edinburgh, ABRO initiated a campaign against this decision, with
journalists, farming bodies and MPs expressing their outrage. This
campaigning led to some concessions, and a separate channel of
funding to offset the most drastic cuts (Myelnikov, 2017, pp. 716–719).
Nevertheless, ABRO still lost 50% of its budget and all its experimental
farms, except for a small extension of land in Dryden, seven miles south
of Edinburgh. In 1983, a young reproductive physiologist, Roger Land,
was appointed as ABRO's new Director. From day one, he approached
the crisis as a cathartic movement that would allow the restructuring of
the institutional architecture of ABRO and an emphasis on novel tech-
niques. One of Land's first decisions was to create a molecular biology
programme within which projects using recombinant DNA and related
technologies could be developed.
To do this, Land built in-house expertise in molecular biology and
attracted a younger generation of scientists. Shortly after his appoint-
ment, he hired Lathe, who had been employed as a researcher in one of
the first European biotechnology start-ups, Transgéne SA in Strasbourg.
Having worked on the development of the recombinant rabies vaccine
for wild animals, Lathe had what was then rare expertise in commercial
biotechnology. At Edinburgh University, Land sought the advice of
John O. Bishop, then based in the sizeable Genetics Department after
many years working with Waddington at the IAG. This resulted in the
recruitment of Bishop's associate, John Clark, who had worked on ge-
netic expression in mice and completed a PhD thesis on human satellite
DNA (García-Sancho, 2015: 291ff).
Clark and Lathe initiated a line of research within ABRO's new
molecular biology programme to devise an “alternative route to direct
animal breeding” via the genetic engineering of “both laboratory and
farm animals.”7 This line of research was formally launched in 1984
and became increasingly known as the pharming project. Unlike pre-
vious research in ABRO, the pharming project did not use farm animals
as sources of meat, milk or wool. Building on the work across species
characteristic of the biotechnology start-up companies, it sought to
transform these animals into “vehicles for the production” of com-
mercially relevant substances via recombinant DNA techniques (Fig. 1).
This use of animals also distinguished Clark and Lathe's work from
Brinster and Palmiter's prior production of transgenic mice and live-
stock: the Edinburgh researchers did not seek to augment the size of the
animals, but to genetically modify sheep in order to express “human
proteins of biomedical importance” in their milk (Lathe et al., 1986, p.
95). Shortly after the start of the project, Lathe left Edinburgh and Clark
became the coordinator of the experimental work.
Once the experiments started, it became clear that the genetic
modification of farm animals would require bridging other things apart
from the mice and the sheep. The way Clark initially approached mice –
as prototypes for producing transgenic sheep – was not that dissimilar
to the previous use of the rodents to design breeding programmes at
ABRO, despite the objectives being different. Nicole Nelson has shown
that using animals in this prototypic way – to model processes that may
or may not be exportable – involves moving “from the specific to the
specific” rather than “from the specific to the general or the simplified
to the complex” (Nelson, 2013, p. 7). Soon after the launch of the
pharming project, Clark realised that the success of the experiments
depended on the creation of an infrastructure – of people, laboratories
and technologies – that could account for the genetic modification of
both mice and sheep. This infrastructure initially emerged from the pre-
existing space of animal breeding in Edinburgh.
For the first five years of the project (1984–89), the mouse side of
the work relied on the University's animal house. This facility had been
used in the previous breeding research and was located within close
distance of ABRO's headquarters, based in the University's life sciences
campus – the King's Buildings – in the southern suburbs of Edinburgh
(Fig. 2). With the start of the pharming project, the animal house be-
came a space of convergence of different mouse experiments, with
Clark's standing as a member of a new generation of geneticists effec-
tively mediating between ABRO's past allies at the University – focusing
on Falconer's predictive methods – and those wanting to venture into
genetic modification.
Genetically modifying sheep, as opposed to mice, required even
rarer expertise in developmental biology. These skills came from within5 ‘Conference Literature, 1981‘, Add. 8388, Anne McLaren Papers, The British
Library (London).
6 For a discussion on how to navigate this multiplicity of actors and interests
in the history of recent biology see García-Sancho, 2016. The annual research
reports on which this article is based combine accounts written by both ad-
ministrative managers and scientists in charge of the experimental work.
7 “Research Programme”, ABRO Annual Report – January 1984, p. 42.
Edinburgh University Main Library, Special Collections, Records of Roslin
Institute and Predecessor Institutions, EUA IN23/1/1/2.
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ABRO, in the figure of Ian Wilmut, a reproductive physiologist with
considerable experience in embryo transfer. Wilmut had joined ABRO
in 1973, after training and working at the ARC Animal Research Station
in Cambridge. His appointment to the new project was not smooth: to
his frustration, Wilmut was forced away by Land from his earlier work
on embryonic mortality in sheep, and asked to help Clark adapt the
genetic engineering system from mouse to farm animals.8
Clark's mouse experiments and Wilmut's research on sheep effec-
tively divided the pharming work between the University's animal fa-
cilities and Dryden farm, located five miles apart (Fig. 2). The institu-
tional space of Edinburgh was further reconfigured when, in 1986, the
Agricultural and Food Research Council (AFRC, as ARC was renamed in
1983) forced ABRO to merge with two other institutions in a move that
sought to streamline scientific programmes and administrative costs –
other AFRC centres were closed altogether. These institutions were the
PRC and the Institute of Animal Physiology in Babraham (Cambridge-
shire).9 The resulting organisation was named the Institute of Animal
Physiology and Genetics Research (IAPGR), a large conglomerate with
two geographically distant stations, one around Cambridge and the
other around Edinburgh. The Edinburgh Research Station was housed
in the old PRC headquarters at Roslin. However, Clark and his colla-
borators did not move until the Roslin facilities opened its own animal
house and mice lived in proximity to rats, rabbits and sheep on the
Dryden farm.10
In 1987, IAPGR researchers, aided by the Scottish Development
Agency, secured investment for Caledonian Transgenics Ltd. – soon
renamed Pharmaceutical Proteins Limited (PPL) – a start-up bio-
technology company to market the deliverables of the pharming pro-
ject. The company provided funding to the project in exchange of ex-
clusive rights over the therapeutic proteins that the transgenic sheep
would produce. These proteins were then expected to be sold to phar-
maceutical companies which would transform them into drugs (Clay &
Goldberg, 1997). PPL worked in close association with the pharming
team, but independently from the IAPGR, hiring its own researchers
and leasing the Edinburgh Research Station's infrastructure.11 The rest
of the funding to pharming came from the Transgenic Animal Pro-
gramme, a grant scheme that the AFRC established one year afterwards
with IAPGR researchers becoming especially successful applicants.
All these scientific and institutional moves show that by the late
1980s, animal biotechnology had shifted from a term in a policy report
to a set of projects, one of which was developed by a team of people
working in different places at Edinburgh. The pharming project had
expanded the collective agency within which animal biotechnology
originated in Britain, and transformed it into an experimental pro-
gramme that went far beyond a simple bridging – or scaling-up – of
genetic engineering from microorganisms to mice and sheep. STS lit-
erature has shown how interspecies work can significantly remake
geography. Friese and Clarke (2012) stressed the importance of
“transposing” infrastructures across species, via the movement of
techniques, or the alliance – or friction – between different people. In
Fig. 1. Left, Gordon's microinjection and micromanipulation system to make transgenic mice. Right, a scheme of the pharming procedure – note the similarities
between both techniques. Sources: Gordon & Ruddle, 1983, p. 413, © Elsevier (left); ABRO Annual Report—January 1985, p.22, reprinted under the Creative
Commons licence, courtesy of the University of Edinburgh Main Library (right).
8 This adaptation required complex micromanipulation experiments: due to a
hand tremor, Wilmut was assisted in the practical aspects of sheep embryo
microinjection by a recent ABRO recruit, Paul Simons (Myelnikov and Garcia-
Sancho, 2017, p. 2).
9 For further discussion on breeding research in the Cambridge area see Polge,
2007.
10 B. Cross to R. Land, 21th October 1986. File relating to the new mouse
accommodation on the Roslin site. Edinburgh University Main Library, Special
Collections, Records of Roslin Institute and Predecessor Institutions, EUA IN23/
3/5/5/1. John Bishop and Richard Lathe, oral history conducted by D.
Myelnikov on 1st March 2016 in Edinburgh.
11 Shortly after the launch of PPL, in 1988, Thatcher's government suddenly
discouraged any public investment in what was defined as ‘near-market’ re-
search – a form of applied work that was too close to commercial viability to
receive state support (Myelnikov, 2017). PPL squared with this new imperative
of moving a substantial part of the funding of applied research to the private
sector and fitted with the way animal biotechnology was being configured in
Britain: in the face of Rothschild and Thatcher's policies, investors and en-
trepreneurs regarded medicine as a safer area than agriculture.
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these processes of transposition, species do travel across space, under-
stood as both a physical territory and in the more metaphoric meaning
of a disciplinary field or funding scheme (see also Davies, 2012; Milne,
2012).
In Edinburgh, the work of exporting recombinant DNA from mouse
to sheep required the collective action of scientists coming not only
from molecular biology, but also from experimental embryology. This
collective action entailed both collaboration and dissent, as exemplified
by Wilmut's enforced move to the pharming project. Moreover, the
production of genetically modified mice and sheep triggered the
transposition of infrastructures that both ABRO and the University of
Edinburgh had created around both organisms over the preceding
decades. The new institutional setting within which the experiments
took place was spread across places that were distant in both a geo-
graphical and more figurative sense: a biotechnology start-up company,
a university animal facility and a research institute with dedicated
government funding for transgenic work and two stations more than
350 miles apart. The mice and sheep with which the Edinburgh re-
searchers worked added further complexity to this assemblage.
4. Back-and-forth between organisms and disciplines
The first protein that the pharming team targeted for commercial
development was alpha-1-antitrypsin, which is used in the treatment of
emphysema and cystic fibrosis. Other laboratories in Britain – notably
University College London – were working with the gene that encodes
the protein and the team relied on the existing networks of gene ex-
change, as well as their own efforts, to obtain and optimise the neces-
sary DNA. Clark's plan was to test the insertion of the human gene that
expresses the protein in mice, select the best gene constructs and inject
these into sheep embryos.12 However, this initial strategy broke down,
as alpha-1-antitrypsin did not behave predictably in mice, and the
parallel sheep work developed faster – especially in the expression of
sufficient levels of protein for therapeutic use. This led the pharming
project to its first striking results with the birth of Tracy.
Tracy produced immense amounts of alpha-1-antitrypsin in its milk
and was born in the Dryden farm in 1990, the same year that the full
pharming team moved to the IAPGR facilities in Roslin (Wright et al.,
1991). While not the first transgenic sheep made in Edinburgh, she was
the first clear success and was widely promoted as such (Fig. 2). For the
first time, the importance of an Edinburgh-bred animal was founded on
the human and medically relevant gene it carried rather than on Tracy
being a sheep or having special qualities for the production of food or
wool.13 It was thus a clear victory for the pharming project, and one
that highlighted the new goals that the Edinburgh scientists were pur-
suing through interspecies, mouse-to-sheep work.
Despite the success of Tracy, this mouse-to-sheep work was be-
coming increasingly convoluted. Nelson has investigated the use of
mice as models for human behaviour and proposed the notion of
“epistemic scaffold” to conceptualise the inferences that researchers
make across species. Since both mouse and human are highly specific
organisms, they require knowledge-generation mechanisms that are
flexible and can be modified over time. Epistemic scaffolds are proto-
cols aimed at generating definite and enduring knowledge; yet, they can
be dismantled and reconfigured at will when new findings alter the
relationship between one organism and the other (Nelson, 2013: 7ff).
Nelson's concept aligns with Friese and Clarke's notion of transposition,
which captures the continuous, back-and-forth movement of knowledge
Fig. 2. Left, map with the location of the different Edinburgh breeding institutions (elaborated by authors from Google Maps). The Cambridge Research Station of the
IAPGR was located in Babraham, 350 miles south from Edinburgh. Right, Tracy, the first successful transgenic sheep born in Roslin in 1990 (courtesy of the Roslin
Institute, reprinted with permission).
12 To conduct the genetic modification experiments, Clark needed the con-
tribution from Alan Archibald, a biochemist who in the hectic years preceding
the AFRC's cuts had visited Heidelberg to train in recombinant DNA technol-
ogies at the European Molecular Biology Laboratory. Archibald carried mice
(footnote continued)
with the alpha-1-antitripsin gene on the train from London to Edinburgh (in-
terview with A. Arcbibald by G. Bulfield. Edinburgh University Main Library,
Special Collections, Records of Roslin Institute and Predecessor Institutions,
EUA CA15/5; Myelnikov and Garcia-Sancho, 2017, pp. 5–6).
13 Social science literature has shown that modern industrial farming renders
animals “invisible” through standardisation processes that often involve genetic
selection and modification (Lonkila, 2017).
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from one organism to another. In this circulation, the similarities or
generalisations on which the modelling relationship is founded often
need serious qualification or dismissal. However, establishing a con-
nection between the two organisms is still a highly productive strategy
and may persuade funders of the potential of an emerging field (Friese
& Clarke, 2012, p. 36ff).
These highly volatile, but ultimately productive processes of
knowledge circulation were all at play in the pharming project, where
work leading to transgenic mice provided the inspiration for the genetic
modification of sheep. More generally, the hypothesis of scaling-up
genetic engineering between these two organisms was a crucial trigger
for the collective agency that resulted in the emergence of animal
biotechnology and the AFRC Transgenic Animal Programme. Yet at the
bench level, the epistemic relationship between the two organisms was
continuously reconfigured and, at some points, inverted in Edinburgh:
when sheep expressed alpha-1-antitrypsin better than mice. Since the
sheep became a reliable organism for molecular intervention in its own
right, mouse and sheep work turned increasingly independent at the
IAPGR, and only connected to address specific experimental problems.
One such problem was the inefficiency of microinjection in both
mouse and sheep. The success rate of injecting foreign genes into the
mouse pronuclei had been low since Gordon's initial experiments at
Yale, and in a well-established lab, the proportion of isolated embryos
that resulted in live transgenic mice was 2% (Camper, 1987). The team
that made Tracy reported an even smaller 0.91% success rate with
sheep (Wright et al., 1991, p. 831). Taking a much longer pregnancy
and higher cost into account, a more efficient way of making transgenic
sheep was a priority. In this case, mouse work paved the way: while the
prototypic relationship between mice and sheep may have been chal-
lenged by the success of Tracy, the more expansive and well-funded
mouse research still served as a major inspiration for what was possible,
scientifically exciting, and a desirable goal.
Since the early 1980s, an alternative way of producing transgenic
mice had been the use of stem cells that could be genetically modified
in culture and introduced into the embryos. This line of research had
originated in cell biology laboratories, with embryonic mouse stem cells
being isolated in Cambridge by Martin Evans and Matthew Kaufman,
and independently by Gail Martin at University of California in San
Francisco (Evans & Kaufman, 1981; Martin, 1981; see also Lancaster,
2017). Their pluripotency was a key feature: due to these being un-
differentiated cells, they could contribute to the embryo's germline and
thus whole mice could be bred from them. Crucially, this meant that
genetic modification could be done in the cells in vitro, with the kind of
selection systems used in bacteria and somatic animal cells – one no
longer had to hope that the gene would interact as expected in an
embryo. Towards the late 1980s, genetic modification of stem cells was
thus becoming a promising tool to improve control over inserted genes,
as well as the success rate of transgenesis.
Some IAPGR researchers, especially those with a cell biology
background, attempted to genetically modify animals via stem cells.
Jim McWhir, a former PhD student of Evans, had moved to Edinburgh
as a postdoctoral fellow and obtained his first grant from the Medical
Research Council to genetically engineer embryonic stem cells in mouse
and explore their potential therapeutic properties (Myelnikov & Garcia-
Sancho, 2017, p. 8). In the mid-1990s, he associated with Wilmut to
assess the potential of stem cells in the genetic modification of sheep
embryos – the AFRC Transgenic Animal Programme accepted applica-
tions for stem cell work. However, unlike with alpha-1-antitrypsin,
embryonic stem cells were more difficult to isolate in sheep than in
mice.
This led Wilmut and McWhir to explore nuclear transfer as an al-
ternative approach. Like stem cells, this technique had previously been
used in embryology and cell biology laboratories with mice, even if
cloning mice through nuclear transfer – reported by Karl Illmensee in
1981 – was later dismissed as fraudulent (Kolata, 1997, pp. 103–133).
Nuclear transfer involved the creation of an artificial embryo by ex-
tracting the nucleus of a cell and inserting it into an enucleated oocyte –
an unfertilised egg that had been previously devoid of its own nucleus.
If the new, inserted nucleus belonged to an adult cell and the resulting
embryo was allowed full-term development, the offspring would be
genetically identical to – a clone of – the cell donor.
The first candidate cell nuclei for nuclear transfer in Edinburgh were
those that McWhir was exploring in his search for embryonic stem cells.
They were sheep embryo nuclei and showed some plasticity, despite
being more differentiated and less pluripotent than the elusive stem
cells. The team decided that the first nuclear transfer experiments
would be conducted in the absence of any genetic modification and, in
1995, Megan and Morag were born in Roslin after the insertion of
McWhir's nuclei into an enucleated oocyte (Campbell, McWhir, Ritchie,
& Wilmut, 1996). One year afterwards Keith Campbell, a recent team
recruit and an expert in developmental cycles, suggested to repeat the
experiment inserting an adult – rather than an embryo – cell nucleus
into the oocyte. This led to the birth of Dolly, the first mammal that was
genetically identical to another adult sheep – the donor of the cell
nucleus (Wilmut, Schnieke, McWhir, Kind, & Campbell, 1997). Both of
these achievements occurred in a renewed institutional setting, since in
1993 the Edinburgh Station of the IAPGR had split with Babraham and
become again an independent institution called the Roslin Institute.
Dolly, Megan and Morag multiplied the layers of complexity of the
mouse-to-sheep work in Edinburgh. Stem cells and nuclear transfer
derived from a different tradition than transgenic technologies, one that
was less connected with altering the structure of genes, and more with
the replication of the DNA molecule in the process of cell and embryo
division. Wilmut, McWhir and Campbell came from an embryology and
cell biology background rather than molecular biology. In producing
the three cloned sheep, they originally modelled their work on mouse,
as they had done in the previous case of Tracy. However, like in Tracy's
genetic modification, they moved beyond the state-of-the-art of re-
search on this organism: the dominant view among life scientists in the
early-to-mid 1990s – especially after Illmensee's fraud allegations – was
that successful nuclear transfer would be difficult, if not unachievable
in mammals (Myelnikov & Garcia-Sancho, 2017, pp. vi-vii and 1). With
the cloning of Megan, Morag and Dolly, sheep work in Edinburgh
moved faster than mouse work.
The planning of the pharming project was to bring together these
different layers of mouse-to-sheep work by recasting stem cells and
nuclear transfer as tools for genetic modification. Following the birth of
Dolly, Wilmut, Campbell and McWhir would produce a transgenic
sheep by transferring to the enucleated oocyte a genetically modified
rather than intact nucleus, ideally from an embryonic stem cell. This
would improve the efficiency of sheep production and, once the suc-
cessful genetically modified sheep were born, the cloning technology
could be used to perpetuate this animal, through the same procedure
that had led to Dolly. At a broader disciplinary level, producing a
cloned and genetically modified sheep, or cloning a successful trans-
genic sheep, would subordinate the embryological and cell biological
techniques to the objectives of molecular biology, thus confirming re-
combinant DNA as a universal tool unifying different fields of the life
sciences.
Six transgenic and cloned sheep were born in Edinburgh in 1997,
one year after the birth of Dolly. The most promising of them was
named Polly and incorporated into her DNA the gene coding for the
human protein factor IX that helps in the treatment of haemophilia
(Schnieke et al., 1997). There were yet some factors that led Polly to
receive far less public attention than Dolly, even in the internal pub-
licity of the Roslin Institute. Firstly, the genetic modification could not
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be conducted in embryonic stem cells, that had remained elusive for
sheep. In that instance, Wilmut, Campbell and McWhir's work always
ran behind that of mouse researchers. Secondly, and more importantly,
the levels of expression of factor IX were insufficient for an industrial
development: PPL did try to market this protein and Tracy's apha-1-
antitrysin, but neither product completed clinical trials.14
Scholars have documented a long and established tradition of work
across species in the reproductive sciences, one that is at least as prolific
as molecular biology (Davies, 2012; Hinterberger, 2018). Friese and
Clarke have shown that work across species around animal reproduc-
tion is populated with “sources of recalcitrance” that prevent the results
from one organism to be generalised to the other. Far from obstructing
transposition, Friese and Clarke argue that those recalcitrant processes
can be enormously creative, leading research to “new opportunities”
and different “sets of questions” (Friese & Clarke, 2012, p. 34 and 46).
The Edinburgh scientists successfully transposed the genetic modifica-
tion and nuclear transfer technologies from mouse to sheep – they ac-
tually overcame some of the sources of recalcitrance derived from the
prior adaptation of these technologies from microorganisms to mice.
However, the commercial expectations attached to this transposition
were never met: the cloned and transgenic sheep did not enable PPL to
market therapeutic proteins. In other words, the exportation of re-
combinant DNA and nuclear transfer from mouse to sheep did not ef-
fectively scale-up commercial biotechnology from microorganisms to
farm animals.
This led Wilmut, Campbell and McWhir to look for alternative ob-
jectives and independent funding. The pharming project's core work on
genetic modification had always been supported by the AFRC – known
as the Biotechnology and Biological Sciences Research Council (BBSRC)
since 1994. However, ahead of the nuclear transfer experiments,
Wilmut applied to and obtained a grant from the Ministry of
Agriculture, Fisheries and Food (MAFF). MAFF had been an important
contractor of the Edinburgh institutions since the time of Rothschild's
reforms. Its political agenda differed substantially from that of the
AFRC and BBSRC in that MAFF was eager to distance itself from any
genetic engineering work, which was too market-oriented and, cru-
cially, controversial at a time in which genetic modification of food –
the GM crops – was increasingly questioned.
MAFF authorities went as far as suggesting any reference to making
transgenic sheep via nuclear transfer be removed from the Dolly paper
draft as well as press releases, and the reproductive potential of cloning
be emphasised instead. Thus, shortly before Dolly was announced to the
world, Wilmut's MAFF liaison queried
“What is meant by the sentence ‘Gene targeting in livestock will
become possible by nuclear transfer from transformed cell popula-
tions’[…]? MAFF does not support research to produce transgenic
livestock animals and the tone of this sentence suggests that the
production of livestock animals might be an aim of your work”.15
As a result of these pressures, as well as the general fascination with
cloning, the Roslin scientists presented Dolly as an end in itself in both
the scientific article and press releases. This led scientific commentaries
and media reports to portray Dolly as a cloned animal rather than a
vehicle for genetic modification (Brown, 2000; Holliman, 2004). The
line of research that had led to the nuclear transfer experiments was
consistently omitted or downplayed in most accounts of the birth of
Dolly. This multiplied the gap between the reproductive scientists and
the core objectives of pharming.
The growing divergence of Dolly's creators from the idea of
pharming moved the project to unexpected territories. Andrew
Pickering has accounted for these serendipitous trajectories in an in-
fluential essay where he compares scientific practice with a “dance; ”
one partner is represented by the researchers equipped with technolo-
gies and the other by the “material agency” of the natural world. The
dance triggers continuous, reciprocal and, crucially, unpredictable in-
teractions, since the behaviour of organisms and other entities from the
natural world cannot be fully predicted or channelled. Scientific prac-
tice is consequently shaped – or mangled – through bidirectional en-
counters between human and material agency: on the one hand, the
objectives of scientists and the (limited) power of their technologies,
and on the other hand the constraints imposed by the natural world.
Time is a crucial variable in this process, since the “mangle of practice”
occurs during the course of projects and leads the goals that were ori-
ginally written in research proposals to be constantly reformulated
(Pickering, 1995, p. 21).
In Edinburgh, the material agency of mice and sheep – embodied in
their different biology – qualified the pharming project's objective of
scaling-up commercial biotechnology to farm animals. In this qualifi-
cation, a multiplicity of actors – not only scientists and technologies –
intervened, among them media, their audiences and funders such as
MAFF, with markedly different interests from the BBSRC. This growing
conglomerate of animals, technologies, individuals, places and institu-
tions exerted a collective agency that differed from the one that had
resulted in the original formulation of animal biotechnology by the ARC
and ABRO: it prioritised cloning and stem cells over the production of
transgenic sheep. In Friese and Clarke's terms, a recalcitrant process led
the practice of nuclear transfer to acquire a life of its own and be
creatively recast beyond the objective of genetic modification.16
This new life of cloning gradually displaced the idea of pharming. In
1999, the Roslin Institute received a six-year grant from the US phar-
maceutical company Geron to investigate the production of human and
animal stem cells. Geron was also a funder of a group at the University
of Wisconsin that had reported the isolation of the first stem cells from
human embryos (Thomson et al., 1998). Human embryonic stem cells
were highly pluripotent and could regenerate damaged tissues, espe-
cially if they were obtained via cloning: a cell nucleus of the patient was
inserted into an enucleated oocyte and transformed into an embryo
from which the stem cells were extracted. This placed Roslin's nuclear
transfer technique as an ideal source of patient-specific stem cells and
led Geron to buy the patent in exchange of the grant. Such level of
funding crucially alleviated the chronic financial problems of the
agricultural sciences in Edinburgh, but at the price of shrinking their
original animal breeding remit.17 Even today, Roslin scientists and most
biotechnology commentators still see the production of stem cells as the
main legacy of Dolly, while the original pharming project has largely
fallen into oblivion.
14 The site of integration of the foreign human gene into the sheep's genome,
as well as post-translational modifications, left the levels of protein expression
largely unpredictable. This, together with the difficulties of producing viable
transgenic sheep, created uncertainties that complicated PPL's commercial de-
velopments. Other companies outside Edinburgh successfully manufactured
products via transgenic animals: an early example of this is Herman the bull,
produced by the Dutch-US firm Pharming in 1990 (Myelnikov and Garcia-
Sancho, 2017, 7 and 27ff.).
15 Letter from MAFF to Ian Wilmut, 7 November 1996, The National Archives
of the UK (TNA): Ministry of Agriculture, Fisheries and Food: Animal Science
and Biotechnology: Registered files (BUB prefix): Development potential of
quiescent cells derived from sheep embryos, sheep foetuses and adult sheep:
Roslin Institute research project LS1202, MAF 662/1.
16 For similar dances of agency in which the behaviour of non-human organ-
isms leads scientists to redefine research objectives see Coppin, 2008 and
Nickelsen, 2017.
17 “Roslin signs six year deal with Geron,” Roslin Institute Annual Report,
1998–99, pp. 14–17. Edinburgh University Main Library, Special Collections,
Records of Roslin Institute and Predecessor Institutions, EUA IN23/4/1/1/1. On
the transition of the AFRC, ABRO, the IAPGR and the Roslin Institute from a
mainly agricultural to an increasingly biomedical focus – embodied in the
change of name of the research council to BBSRC in 1994 – see Myelnikov, 2017
and García-Sancho, 2015.
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5. Conclusion
Historians have paid increasing attention to the tradition of animal
breeding in Edinburgh and, more specifically, the line of research on
genetic engineering within which Dolly was born (Button, 2017;
García-Sancho, 2015; Myelnikov, 2017). In this article, we have argued
that the genesis of that line of research – called the pharming project –
and its transition from animal transgenesis to human regenerative
medicine can only be fully captured by looking at how the Edinburgh
scientists worked across mice and sheep during the last quarter of the
twentieth century. More fundamentally, and in line with existing his-
toriography (Kirk & Worboys, 2011; Mason Dentinger & Woods, 2018),
this mouse-to-sheep perspective offers new insights on the ways biology
and medicine, human and animal health, and reproductive and mole-
cular science interacted during the 1980s and 1990s, a time of financial
uncertainty for agricultural research.
The will of the pharming scientists to export genetic modification
technologies from mouse to sheep both built on a longstanding tradition
of work across these two organisms in Edinburgh and reconfigured
existing objectives of interspecies work. In this reconfiguration, the
mice and the sheep were as important as the stated objectives of the
project: diverging experimental results across these two organisms
challenged modelling assumptions that were based on the imagined
capacity of recombinant DNA to bypass biological barriers. Laboratory
and farm animals formed a conglomerate with neoliberal policies, sci-
ence administrators and biological researchers from many fields. All
these actors exerted a collective and historically contingent agency that
shaped the identity of animal biotechnology: whereas in the 1980s this
identity was more oriented to genetic modification, it gradually shifted
towards stem cells and regenerative medicine. The resistance of the
organisms to over-simplistic modelling and the entrance of new actors
into the conglomerate – from places as diverse as the media and bio-
business – were key to this reorientation.
Investigating animal biotechnology from an interspecies perspective
provides a new lens to analyse the birth of Dolly. Sarah Franklin bor-
rowed “the very conservative idiom of genealogy” to argue that “Dolly
came onto the scene for a whole flock of reasons that connect her,
Roslin, bioscience, cloning, stem cells, and a myriad other biocultural
entities together through lineages that are familiar, and even tradi-
tional, but newly hybridized, or mixed” (Franklin, 2007, p. 13). By
inserting mice into the equation and looking at how this organism in-
spired experimental work on sheep, we have proposed the pharming
project as a complementary narrative, one that does not place Dolly at
the centre of the stage, neither makes her birth be regarded as in-
evitable. Yet the relationship of the pharming project with Dolly is not
as clear as it may seem at a first glance. If we interpret that pharming
finishes with the genetic modification of sheep, Dolly would be just one
of the constitutive genealogies of this project, along with Thatcherite
policies, genetic engineering techniques and the reconfiguration of the
agricultural sciences. If we alternatively identify stem cell research as
the most definite – and successful – outcome of the pharming idea,
Dolly would be the turning point that reconfigured the fate of the
project. In all scenarios, the birth of Dolly appears as a contingent
phenomenon, the product of a broader line of research rather than the
primary or sole objective of scientists.
At a more general historiographical level, the reconfiguration of
animal breeding in Edinburgh challenges existing assumptions about
how molecular and developmental biology interacted at the fall of the
twentieth century. Historians have argued that the transition of ex-
perimental research from microorganisms to higher organisms was the
main reason why molecular biologists incorporated embryological
perspectives from the mid-1970s onwards (e.g. Morange, 2000). Our
story suggests that, in this incorporation, embryologists were as
proactive as molecular biologists and showed both the limitations of
and alternatives to a purely genetic approach. Ian Wilmut, Jim McWhir
and Keith Campbell were not involved in the original pharming idea
and incorporated a different way of working across mice and sheep, one
that was based on stem cells and nuclear transfer instead of genetic
engineering techniques. The lasting legacy of Dolly over Polly suggests
that despite the promise of genetic engineering, cell and developmental
biology also exerted a lasting influence within and beyond agricultural
science, in fields such as regenerative medicine. Our paper, conse-
quently, chimes with other historians who have stressed the importance
of the reproductive sciences in the making of biotechnology, a field
commonly – and narrowly – associated with molecular biology
(Wilmot, 2007, pp. 303–315). We also align with recent proposals of
investigating the history of twentieth century agricultural science be-
yond a narrow focus on genetics (Meunier & Nickelsen, 2018).
In 2008 Wilmut, considered by many the father of Dolly, announced
that he would stop using nuclear transfer in the face of new advance-
ments that had made this technique unnecessary to obtain patient-
specific stem cells. That same year, he became the founding director of
the Centre for Regenerative Medicine, a new Edinburgh-based institu-
tion supported by the Medical Research Council rather than the
Biotechnology and Biological Sciences Research Council, the traditional
funder of the Roslin Institute and all its predecessor institutions. This
shows that by the early twenty first century regenerative medicine had
established itself as an independent field from the tradition of animal
genetics and agricultural research in Edinburgh. Our paper has re-
constructed this connection by exploring how Wilmut and his collea-
gues worked across mice, sheep and, ultimately, humans. This has en-
abled us to offer an account that historicises the birth of Dolly and, at
the same time, raises a new perspective on the emergence of animal
biotechnology.
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